Table 2.
Demographic and baseline characteristics
|
Characteristics
|
E group (n = 46)
|
M group (n = 45)
|
χ2
|
P value
|
| Sex, n (%) | 0.029 | 0.865 | ||
| Male | 33 (71.7) | 33 (73.3) | ||
| Female | 13 (28.3) | 12 (26.7) | ||
| Age (yr) | 63.4 ± 8.5 | 58.4 ± 10.1 | - | 0.092 |
| Etiology, n (%) | 0.909 | 0.952 | ||
| HBV | 38 (82.7) | 39 (86.8) | ||
| HCV | 4 (8.7) | 2 (4.4) | ||
| HBV + HCV | 2 (4.3) | 2 (4.4) | ||
| Alcohol | 2 (4.3) | 2 (4.4) | ||
| Child-Pugh stage, n (%) | 0.297 | 0.586 | ||
| A | 25 (54.3) | 27 (60) | ||
| B | 21 (45.7) | 18 (40) | ||
| BCLC stage, n (%) | 0.271 | 0.873 | ||
| A | 7 (15.2) | 6 (13.3) | ||
| B | 19 (41.3) | 21 (45.7) | ||
| C | 20 (43.5) | 18 (40) | ||
| Tumor location | 0.837 | 0.658 | ||
| Right lobe | 30 (65.2) | 28 (62.2) | ||
| Left lobe | 9 (19.6) | 10 (22.2) | ||
| Right and left lobes | 7 (15.2) | 7.1 ± 1.6 | ||
| Mean tumor diameter (cm) | 6.8 ± 2.9 | - | 0.765 | |
| Portal vein thrombus | 0.098 | 0.754 | ||
| Present | 24 (52.2) | 22 (48.9) | ||
| Absent | 22 (47.8) | 23 (51.1) | ||
| Previous treatment | 1.639 | 0.925 | ||
| Surgery | 7 (15.2) | 6 (13.3) | ||
| MWA/RFA | 9 (19.6) | 7 (15.6) | ||
| TACE | 4 (8.7) | 5 (11.1) | ||
| Radiation | 4 (8.7) | 6 (13.3) | ||
| TACE + MWA/RFA | 2 (4.3) | 3 (6.7) | ||
| None | 20 (43.5) | 18 (40) | ||
| AFP [ng/mL, median (IQR)] | 137 (9.8, 970.1) | 114.9 (3.7, 725.7) | - | 0.734 |
| APF grade, n (%) | 2.689 | 0.636 | ||
| 1 | 5 (10.9) | 6 (13.3) | ||
| 2 | 15 (32.6) | 16 (35.6) | ||
| 3 | 11 (23.9) | 14 (31.1) | ||
| 4 | 9 (19.6) | 7 (15.6) | ||
| 5 | 6 (13) | 2 (4.4) |
HCV: Hepatitis C virus; BCLC: Barcelona Clinic Liver Cancer; MWA: Microwave ablation; RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization; AFP: Alpha-fetoprotein; IQR: Interquartile range; APFs: Arterioportal fistulas.